|
Age (years, median/range)
|
61 (21–87)
|
|
Gender (F/M)
|
432/364
|
|
Body Mass Index (kg/m2, median, range IQR)
|
24.23 (21.9-27.18)
|
|
Follow up (weeks, median, range IQR)
|
35.14 (23–55.4)
|
|
Follow up completed (n° pts/total pts)
|
535/796
|
|
Length of use (weeks, median, range IQR)
|
22.71 (10.1-41.9)
|
|
Time of in-situ permanence (weeks, median, range IQR)
|
33.71 (15.71-57)
|
|
Pancreatic cancer (n° pts)
|
20
|
|
Colon/rectal cancer
|
218
|
|
Gastric cancer
|
67
|
|
Oesophageal cancer
|
102
|
|
Lymphoma
|
29
|
|
Breast cancer
|
127
|
|
Brain cancer
|
14
|
|
Head and neck cancer
|
33
|
|
Sarcoma
|
48
|
|
Liver cancer
|
15
|
|
Lung cancer
|
36
|
|
Ovarian cancer
|
38
|
|
Melanoma
|
13
|
|
Urothelial cancer
|
6
|
|
Teratoma
|
5
|
|
Other miscellaneous
|
25
|
|
White blood cells count (cells ×109/L, median, range IQR)
|
6 (1.98-8.77)
|
|
Hb (g/L, median, range IQR)
|
12 (10–13)
|
|
Platelets (cells × 109/L, median, range IQR)
|
276 (223–341.5)
|
|
PT (%, prothrombin time, median, range IQR)
|
88 (75–100)
|
|
PTT (sec, partial thromboplastin time, median, range IQR)
|
28 (26–30)
|
|
INR (international normalized ratio, median, range IQR)
|
1,00 (0.5-1.12)
|
